Transgene SA 2016 IR
The report highlights Transgene's clinical development strategy in 2016, focusing on combining its immunotherapies with immune checkpoint inhibitors. The company signed key clinical collaboration agreements for TG4010 and TG4001 and progressed several clinical trials. Transgene also strengthened its financial structure with a €20 million loan from the European Investment Bank and a €46.4 million rights issue, extending its financial visibility through 2018. Additionally, the company completed its reorganization by outsourcing bio-manufacturing and selling its production assets to ABL Europe, resulting in a significant reduction in operating expenses.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2016
Type: IR
Pages: 184
Back to company
Transgene SA
Registration Document
The report highlights Transgene's clinical development strategy in 2016, focusing on combining its immunotherapies with immune checkpoint inhibitors. The company signed key clinical collaboration agreements for TG4010 and TG4001 and progressed several clinical trials. Transgene also strengthened its financial structure with a €20 million loan from the European Investment Bank and a €46.4 million rights issue, extending its financial visibility through 2018. Additionally, the company completed its reorganization by outsourcing bio-manufacturing and selling its production assets to ABL Europe, resulting in a significant reduction in operating expenses.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Apr 13, 2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Employees